Gemcitabine in patients with solid tumors and renal impairment: A pharmacokinetic phase I study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 3, 2004, Pages 289-293

  Delaloge, Suzette ^a,e   Llombart, Antonio ^a   Di Palma, Mario ^a   Tourani, Jean Marc ^b   Turpin, Francois ^c   Ni, Lan ^d   Forgue, S T ^d   Le Chevalier, Thierry ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b Hopital Laennec   (France)

^c CENTRE RENÉ HUGUENIN   (France)

^d ELI LILLY AND COMPANY   (United States)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Advanced cancer; Gemcitabine; Pharmacokinetics; Renal impairment; Solid tumors

Indexed keywords

BETA 2 MICROGLOBULIN; DEOXYURIDINE DERIVATIVE; DIFLUORODEOXYURIDINE; DRUG METABOLITE; EDETATE CHROMIUM CR 51; GEMCITABINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HEMATOLOGIC DISEASE; HEMATURIA; HUMAN; KIDNEY FAILURE; LEUKOPENIA; MALE; METASTASIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PROTEINURIA; RECURRENT CANCER; SOLID TUMOR; THROMBOCYTOPENIA;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; FLOXURIDINE; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; NEOPLASMS;

EID: 2942588389     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.COC.0000071382.14174.C5     Document Type: Article

References (12)

1. Carmichael J. The role of gemcitabine in the treatment of other tumours [review]. Br J Cancer 1998;78(suppl 3):21-5.
2. 2) levels. Invest New Drugs 1997;15:115-21.
3. Hui YF, Reitz J. Gemcitabine: a cytidine analogue active against solid tumors [review]. Am J Health Syst Pharm 1997;54:162-70.
4. Gietema JA, Groen HJ, Meijer S, et al. Effects of gemcitabine on renal function in patients with non-small cell lung cancer. Eur J Cancer 1998;34:199-202.
5. Kaye SB. Gemcitabine. Current status of phase I and II trials. J Clin Oncol 1994;12:1527-31.
6. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-40.
7. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1821-6.
8. Allerheiligen S, Patel B, Dhahir P, et al. Population pharmacokinetic analyses: effect of age, gender, duration of infusion, and body surface area on gemcitabine pharmacokinetics. Pharm Res 1995;12(suppl): S327.
9. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine [review]. Semin Oncol 1997;24(suppl 7):S7-2-7.
10. Brochner-Mortensen J. Routine methods and their reliability for assessment of glomerular filtration rate in adults, with special reference to total [51 Cr]EDTA plasma clearance. Dan Med Bull 1978;25:181-202.
11. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics [review]. Annu Rev Pharmacol Toxicol 1992;32:185-209.
12. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and Leukemia Group B 9565. J Clin Oncol 2000;18:2780-7.